Emerging evidence suggests that axial spondyloarthritis (axSpA) should not be seen as a
predominantly male disease, as the non-radiographic form occurs with roughly equal …

Objectives MAXIMISE (Managing AXIal Manifestations in psorIatic arthritis with
SEcukinumab) trial was designed to evaluate the efficacy of secukinumab in the …

Objective. To assess skin elasticity in systemic sclerosis (SSc) by using a new imaging
modality, ultrasound elastography (UE). Methods. Our study included 18 consecutive …

OBJECTIVE: To evaluate by clinical, laboratory, and sonographic assessment the effects of
adalimumab therapy in patients with rheumatoid arthritis (RA) over 24 months of treatment …

Background Secukinumab (SEC) has provided significant and sustained improvement in the
signs and symptoms of active psoriatic arthritis (PsA) and ankylosing spondylitis 1. Evidence …

We evaluated clinically and sonographically the effects of etanercept therapy in patients with
rheumatoid arthritis (RA) over 12 months of treatment. Eighteen patients affected by RA who …

Introduction Secukinumab, a fully human monoclonal antibody that directly inhibits
interleukin-17A, has demonstrated robust efficacy in the treatment of moderate to severe …

Objective. To investigate the role of a new hybrid imaging modality, integrated in the US
equipment and derived by a real-time MRI and US fusion process, in the hand and wrist …

Objective Real‐world studies are needed to identify factors associated with response to
biologic therapies in patients with axial spondyloarthritis (SpA). The objective was to assess …

Objectives. To evaluate, by musculoskeletal ultrasound (MSUS), articular involvement in
primary SS (pSS) patients by analysing hand and wrist changes, and to correlate them with …